Progresses in DC-CIK adoptive cellular immunotherapy in treatment of hepatocellular carcinoma

doi:10.3969/j.issn.1009-976X.2014.02.029

Abstract

Abstract: 【Abstract】〓Hepatocellular carcinoma (HCC) is the most common malignant tumor in China. HCC is difficult to find and confirm in early stage. Most of patients were in advanced stage when the symptom or signs were presented.The various treatments of HCC,.such as liver resection, transplantation, local ablation, chemotherapy, and molecular targeted therapy, have not improved the 5-years survival rate efficiently. Cell-based therapies is now gaining more and more attention since some success have been achieved, and DC combined CIK cells therapy is one of these attempts. DC and CIK cells are two important factors for cancer immunotherapy..The interaction between them and induced immune response are important parts of the treatment. The advance of DC-CIK cell therapy for HCC is reviewed in this paper.

Key words: DC combined CIK cells immunotherapy, Hepatocellular carcinoma (HCC)

摘要： 【摘要】〓原发性肝癌(以下简称肝癌)临床往往较难早期发现,确诊时往往病情已进入中、晚期,病死率高。目前肝癌的治疗主要是以手术切除、肝移植、局部消融、化学治疗栓塞及其他局部区域治疗、分子靶向治疗等,但这些方法的治疗效果并不理想,患者5年存活率仍然较低。目前细胞免疫治疗现在得到了越来越多的重视,采用树突状细胞(DC)联合细胞因子诱导的杀伤细胞(cytokine induced killer, CIK)的细胞免疫治疗是其中方法之一。DC和CIK细胞是恶性肿瘤免疫治疗的两个重要因素,两者之间的相互作用及所诱发的免疫应答是免疫治疗的重要部分。现就DC-CIK过继细胞治疗原发性肝癌的研究进展予以综述。

关键词: DC-CIK过继细胞免疫治疗, 原发性肝癌

CLC Number:

R657

Zu Yuqi, Xue Pin. Progresses in DC-CIK adoptive cellular immunotherapy in treatment of hepatocellular carcinoma [J]. Lingnan Modern Clinics in Surgery, 2014, 14(02): 214-216.

祖余琪薛平. DC-CIK过继细胞免疫治疗原发性肝癌的研究进展[J]. 岭南现代临床外科, 2014, 14(02): 214-216.

References

[1]张晶.黏附分子与肿瘤免疫逃逸.实用肿瘤杂志，2004，19（5）：449-452.
[2]Steinman RM,Cohn ZA.Idetification of a novel cell type in peripheral lymphoid organs of mice.I.Morphology,quantitation,tissue distribution[J].J Exp Med,1973,137(5):1142-1162
[3]Nagaraj S,Ziske C,Schmidt Wolf IG.Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral in terleukin-2 gene transfer[J].Genet Vaccines Ther,2004,2(1):12.
[4]Rosenberg SA,Dudley ME.Adoptive cell therapy for the treatment of patients with metastatic melanoma[J].Curr Opin Immunol,2009,21(2):233-240.
[5]Sangiolo D.Cytokine induced killer cells as promising immunotherapy for solid tumor[J].J Cancer,2011,2:363-368
[6]Niam M,Linn YC.Fook Chong S,et al.Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy[J].Exp Hematol .2011,39(9):897-903.
[7]Lu XC,Yang B,Yu RL,et al.Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse laege B-cell lymphoma[J]. Cell Biochem Biophys,2012,62,(1):257-265.
[8]Yu J,Ren X,Li H,et al.Synergistic effect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors[J]. Cancer Biother Radiopharm,2011,26(4):485-494.
[9]Ge W,Li CH,Zhang W.et al.Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo[J].Zhonghua Xue Ye Xue Za Zhi,2004,25(5):277-180.
[10] Marten A,Ziske C,Schottker B,et al.Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations[J].J Immunother,2001,24(6):502-510.
[11]Schmidt J,Eisold S,Buchler MW,et al.Dendritic cells reduce number and function of CD4+ CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma[J].Cancer Immunol Immunother,2004,53(11):1018-1026.
[12]张嵩，张尚权，白春学.树突状细胞与同源细胞因子诱导的杀伤细胞共同培养细胞在肿瘤免疫治疗中的作用[J].中华结核和呼吸杂志，2004（5）：315-319.
[13]陈宝安，李曼，孙载阳，等.DC与CIK共同培养对肝癌细胞杀伤活性的研究[J].临床医学.2010,30(1)16-18.
[14]马洪波，黄涛，韩风，陈伟瑜.DC-CIK细胞联合手术治疗原发性肝癌的临床研究[J].重庆医科大学学报，2012（37-11）980-983.
[15]王郑.DC-CIK细胞联合手术治疗原发性肝癌的临床研究[J].中国医药导报，2012，9（25）61-64.
[16]张扬，谭岩，刘冰.DC-CIK细胞治疗联合微创介入治疗原发性肝癌的临床研究[J].中国实用医药杂志，2012，8-7（23）103-104.
[17]Hao MZ,Lin HN,Ye YB,et al．Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma:a comparative study.Chin J Cancer,2010,29:182-189.
[18]Shi M,Zhang B,Rong Z,et al.Autologous cytokine induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma．Wor1d J Gastroenterol，2004，(10)1146—1151．
[19]李建旺，彭大为，黄春珍，元建华.自体CIK细胞及DC细胞联合索拉菲尼治疗晚期肝癌的临床观察[J].实用癌症杂志，2011,9（26-5）459-461.
[20]钱其军，吴孟超.肿瘤过继细胞治疗--老故事新演绎[J].中国肿瘤生物治疗杂志,2011,(18)1-5.